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The introduction and the extended clinical use of nilotinib in thefirst-line treatment of chronic myeloid leukemia have been basedon company-sponsored trials. Independent confirmations are
extremely important. We report an investigator-sponsored study of nilo-
tinib 300 mg twice daily  in 130 chronic myeloid leukemia patients in
early chronic phase. A deep molecular response was achieved in 46%
(MR4.0) and 17% (MR4.5) of patients at 2 years; 58% of the enrolled
patients achieved a MR4.0 at least once, with a sustained MR4.0 in 52% of
them. With a median observation of 29 months (range 24-37 months),
77% of patients were still on treatment with nilotinib. The reasons for
permanent discontinuation were: 3% progression, 5% failure or subop-
timal response, 8% adverse events, 1% treatment-free remission, and
5% other reasons. Thirteen thrombotic arterial events were reported in
12 patients. A prospective evaluation of metabolic effects showed an
increase of fasting glucose without significant variations of glycated
hemoglobin, an increase of total cholesterol (both low density lipopro-
tein and high density lipoprotein fractions) and a decrease of triglyc-
erides. This study confirms a high and rapid efficacy of nilotinib 300 mg
twice daily and provides detailed information on the type and incidence
of non-hematologic and metabolic adverse events (clinicaltrials.gov identi-
fier:01535391). 
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ABSTRACT
Introduction
Nilotinib is a second generation BCR-ABL1 tyrosine
kinase inhibitor (TKI).1 It has been approved for the first-line
treatment of newly diagnosed, chronic phase (CP)
Philadelphia chromosome-positive (Ph+), BCR-ABL1-posi-
tive (BCR-ABL1+) chronic myeloid leukemia (CML), fol-
lowing the report of a company-sponsored phase 3
prospective randomized trial (ENESTnd) comparing nilo-
tinib to imatinib 400 mg once daily (OD).2 Several updates
of the study, over 6 years, have confirmed the initial find-
ings that nilotinib was superior to imatinib for any degree
of molecular response, and for the rapidity of the
response.3,4 The progression-free survival (PFS) was reported
to be marginally improved and no difference in overall sur-
vival (OS) was detectable.3,4 In the ENESTnd trial, two dif-
ferent nilotinib doses were tested, namely 300 mg twice
daily (TD) and 400 mg TD.2-4 The 300 mg TD dose was
selected for approval because it was reported to be as effec-
tive as, but less toxic than, the 400 mg TD dose. A relevant
issue was the cardiovascular toxicity, with focus on arterial
occlusive events (ischemic heart disease (IHD), peripheral
arterial occlusive disease (PAOD) and ischemic cerebrovas-
cular events, ICVEs), that at 5 years were reported in 2.1%
of patients in the imatinib arm, in 6.8% of patients in the
nilotinib 300 mg TD arm, and in 12.6% of patients in the
nilotinib 400 mg TD arm.3
This concern was raised and reinforced by other inde-
pendent studies, for the most part retrospective and mainly
in second-line treatment, reporting a significant incidence of
cardio-vascular adverse events (CVAEs) during nilotinib
treatment.5-9 With a minimum observation of 24 months,
the molecular response rates in a second single-arm compa-
ny-sponsored study of nilotinib 300 mg TD, the ENEST1st
trial, were even higher compared to the ENESTnd results,
with consistent safety data.10 There are no independent,
investigator-sponsored studies of the drug in first-line treat-
ment, with the exception of the two small pilot studies that
were performed prior to the approval of nilotinib in first-
line treatment, at the dose registered for second-line treat-
ment (400 mg TD).11-14 When the 300 mg TD dose became
the standard in first-line therapy, the GIMEMA CML
Working Party designed a prospective phase 3b single-arm
trial of nilotinib 300 mg TD, to independently assess the
efficacy and safety. Since all patients have now been fol-
lowed for a minimum of two years, we herein report the
results of the main analysis of response and adverse events
(AEs).
Methods
A phase 3b single-arm study of nilotinib, 300 mg TD was con-
ducted in adult patients with newly diagnosed CP BCR-ABL1+
CML (clinicaltrials.gov identifier:01535391). A dose increase to 400
mg TD was scheduled for suboptimal response or failure (2009
European LeukemiaNet, ELN, criteria),15 excluding disease progres-
sion, in the absence of toxicity or relevant BCR-ABL1 mutations.
Pre-treatment with imatinib for up to 30 days was permitted. The
primary endpoint was the rate of MR4.0 at 24 months. The second-
ary endpoints are detailed in the Online Supplementary Table S1.
The study was reviewed and approved by the Internal Review
Board of all the participating institutions. The cut-off date for this
analysis was June 30, 2015. 
The detection of a Ph chromosome and/or a BCR-ABL1 fusion
gene associated with consistent morphologic features were
required to confirm the CML diagnosis and the chronic (CP), accel-
erated (AP) or blast disease phase (BP) were defined according to
current ELN criteria.16 Risk scores were calculated according to
Sokal,17 Euro,18 and EUTOS19 formulations. The molecular
response (MR) was assessed by peripheral blood RT-PCR, accord-
ing to the International Scale (IS).20 Definitions: early molecular
response (EMR), BCR-ABL1 transcript ≤ 10% at 3 months; major
molecular response (MMR or MR3.0), BCR-ABL1 transcript 
≤ 0.1%; MR4.0 and MR4.5, BCR-ABL1 transcript ≤ 0.01%, and 
≤ 0.0032%, respectively, in samples with > 10,000, and > 32,000
ABL1 copies, respectively;21,22 sustained MR4.0 or MR4.5, stable
response for > 1 year with > 3 evaluable tests. Molecular tests were
performed every 3 months. The cytogenetic response was
assessed by chromosome banding analysis at 3, 6 and 12 months;
if there were < 20 available metaphases, a fluorescence in situ
hybridization (FISH) analysis on peripheral blood cells was accept-
ed (complete cytogenetic response, CCyR, ≤1% of BCR-ABL1 pos-
itive nuclei, > 200 nuclei analyzed).16 Mutational analysis of BCR-
ABL1 kinase domain point mutations (Sanger Sequencing) was
performed in case of progression, failure or suboptimal
response.15,23 OS, PFS, and event-free survival (EFS, or survival
without treatment discontinuation) were calculated from treat-
ment start until death (OS), until death or progression to AP or BP
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Table 1. Patient characteristics at diagnosis.
Patients, N 130
Age, years;  median (range) 50 (18 - 85)
Age ≥ 65 years, N (%) 25 (19)
Sex, male, N (%) 84 (65)
ECOG ≥ 1, N (%) 21 (16)
Hb level, g/dL; median (range) 12.0 (7.6 - 16.3)
Platelet count, 103/L; median (range) 396 (101 - 4093)
WBC count, 103/ L; median (range) 41.5 (1.8 – 363.2)
Blast cells in PB, %; median (range) 1.0 (0 – 14.0)
Eosinophils in PB, %; median (range) 2.0 (0 – 10.0)
Basophils in PB, %; median (range) 2.2 (0 – 13.0)
Spleen, cm; median (range) 1 (0 - 26)
Palpable spleen, N (%) 67 (52)
Sokal score, N (%):
Low 56 (43)
Intermediate 47 (36)
High 27 (21)
Euro score, N (%):
Low 61 (47)
Intermediate 62 (48)
High 7 (5)
EUTOS score, N (%):
Low 120 (92)
High 10 (8)
CCA/Ph+, present, N (%) 4 (3)
Variant translocations, present, N (%) 8 (6)
Pre-treatment, N (%):
Imatinib 7 (5)
Hydroxyurea 69 (53)
Anagrelide 1 (1)
ECOG: performance status according to the Eastern Co-operative Oncology Group
grading; Hb: hemoglobin; WBC: white blood cells; PB: peripheral blood; EUTOS:
European Treatment and Outcome Study; CCA/Ph+ : clonal chromosome abnormalities
in Ph-positive cells.
(PFS), or until death, progression to AP or BP, failure on nilotinib or
nilotinib treatment discontinuation for any cause, except treat-
ment-free remission (EFS), respectively. Probabilities of OS, PFS
and EFS were calculated using the Kaplan-Meier method.24 Patients
who discontinued nilotinib and patients who underwent allogene-
ic stem cell transplantation were not censored for OS and PFS.
The rates of molecular and cytogenetic response "at" milestones
were calculated by dividing the number of responders at that time-
point by the number of all enrolled patients. The time to response
was calculated from treatment start until the first achievement of
the response. The cumulative probability of response was calculat-
ed taking into consideration the presence of competing risks (fail-
ure, progression or death).25,26
The AEs were graded according to the NCI Common
Terminology Criteria for Adverse Events version 4.0 (CTCAE
v4.0). Lipid modifications were graded according to adapted
American Association of Clinical Endocrinologists (AACE)
criteria,27 and glucose abnormalities according to adapted
American Diabetes Association (ADA) criteria.28 
Results
Baseline characteristics
One hundred and thirty patients were enrolled between
December 2011 and November 2012 at 32 GIMEMA
Clinical Centers. The baseline characteristics of the patients
are shown in Table 1. The median age was 50 years. Sixty-
five percent were males. High-risk patients were 21% by
Sokal, 5% by EURO, and 8% by EUTOS scores. Clonal
chromosome abnormalities in Ph+ cells were reported in
3% of patients. 
Patient disposition
The median follow-up was 29 months (range 24-37
months). The patient disposition at the last contact is
shown in Table 2. Overall, 77% of patients were still on
nilotinib (80% at 2 years), mainly at the initial 300 mg TD
dose. In 6 patients the nilotinib dose was escalated to 400
mg TD due to the absence of an optimal response: 4
patients are still on treatment, 2 of them with an optimal
response and 2 without significant improvements, while 2
patients definitively discontinued nilotinib as a result of
treatment failure. Twenty-eight patients permanently dis-
continued nilotinib, of whom 11 (8%) were due to failure.
Four of these patients progressed to AP or BP after 1, 4, 6,
and 19 months, respectively; all these patients were alive at
last contact. One of these  patients, a 41 year old with an
intermediate Sokal score, developed a lymphoid blast crisis
with T315I mutation and was treated with conventional
chemotherapy followed by allogeneic stem cell transplanta-
tion (alloSCT). A second patient, a 46 year old with an inter-
mediate Sokal score, progressed to AP with V280A muta-
tion and was treated with dasatinib. The third of these
patients, a 32 year old with a low Sokal score, progressed to
AP with clonal evolution and myelodysplastic features,
without BCR-ABL1 mutations, and was submitted to
alloSCT. The fourth and final patient, a 43 year old with a
low Sokal score, progressed to a myeloid blast phase with-
out BCR-ABL1 mutations and is on second-line treatment
with dasatinib (Online Supplementary Table S2). Eleven
patients (8%) discontinued nilotinib for toxicity, one patient
(1%) decided to discontinue the treatment because of stable
deep molecular response, achieving a treatment-free remis-
sion (duration of nilotinib treatment and duration of stable
MR4.0 before discontinuation, 35 and 23 months, respective-
ly), and 5 patients (4%) discontinued for other reasons,
including withdrawal of informed consent and pregnancy.
Two patients (2%) were lost to follow-up. Overall, 3
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Table 2. Patient disposition at  last contact.
Patients, N 130
Still on nilotinib, N (%) 100  (77%)
600 mg 89  (68%)
< 600 mg 7   (5%)
800 mg 4   (3%)
Discontinued nilotinib, N (%) 28  (22%)
Progression to advanced phase 4  (3%)
Failure or suboptimal response 7  (5%)
Adverse events 11  (8%)
Treatment-free remission  1   (1%)
Other causesa 5   (4%)
Lost to follow-up, N (%) 2   (2%)
adetails of other causes: pregnancy, 2 patients, withdrawal of informed consent, 1 patient,
low compliance, 1 patient, alcohol abuse, 1 patient.
Figure 1. Cumulative incidence of deep molecular response. (A) MR4.0: the 
2-year estimated cumulative incidence of MR4.0 was 51% (95% CI, 42-60%), B)
MR4.5: the 2-year estimated cumulative incidence of MR4.5 was 24% (95% CI, 16-
31%). The cumulative probability of achieving a response was calculated under
consideration of competing risks, defined as failure followed by treatment
change, progression or death.
A
B
patients underwent alloSCT, 2 after transformation to AP
(previously described) and 1 after resistance to all TKIs,
including ponatinib, without progression and without
detectable BCR-ABL1 mutations.
Responses and outcome 
According to the intention-to-treat (ITT) principle, 70%
of patients were in CCyR at 6 months, and 77% at 12
months. The 3-month EMR was achieved in 80% of
patients (ITT). The rates of MMR, MR4.0, and MR4.5 at 3, 6,
12, 18, and 24 months are shown in Table 3. At 24 months,
according to the ITT principle, 65% of patients were in
MMR, 46% were in MR4.0, and 17% were in MR4.5. Overall,
75/130 patients (58%) achieved a MR4.0 at least once and
39/75 (52%) achieved a sustained MR4.0; 40/130 patients
achieved a MR4.5 and 11/40 (28%) a sustained MR4.5. The
cumulative probability of achieving MR4.0 and MR4.5 is
shown in Figure 1; after two years of treatment the proba-
bilities were 51% (95% CI, 42-60%) and 24% (95% CI, 16-
31%), respectively. The duration of observation is still too
short for a detailed analysis of the stability of deep molecu-
lar response.
Only 1 patient died, due to the worsening of a pre-exist-
ing comorbidity (chronic obstructive pulmonary disease: a
worsening of general clinical conditions, followed by a
switch to imatinib with a stable response, was observed).
As shown in Figure 2, the 30-month OS was 99% (95% CI
91-100%), the 30-month PFS was 96% (95% CI 89-98%)
and the 30-month EFS (survival without treatment discon-
tinuation, except  for treatment-free remission) was 76%
(95% CI 67-83%).  
Safety
A grade 3-4 thrombocytopenia and neutropenia were
recorded in 8% and 9% of patients. Hematologic AEs
caused early permanent treatment discontinuation in 2
patients. Twenty-five AEs listed under a comprehensive
definition of cardiovascular AEs (CVAEs) were reported in
21 patients (16%): arterial thrombosis, 13 events (Table 4);
venous thrombosis, 4 events (1 deep venous thrombosis, 3
superficial thrombophlebitis); QTc prolongation, 3 events
(only 1 case > 500 msec); arrhythmias, 3 events (2 atrial fib-
rillations, 1 atrial-ventricular blockade); congestive heart
failure, 1 event; acute pericarditis, 1 event. They were
reported as a grade 3 event in nine cases, and as a grade 4
event in one case. The treatment was temporarily discon-
tinued for 9 events in 8 patients (36% of CVAEs, 6% of all
patients), and it was permanently discontinued for 8 events
(32% of CVAEs, 6% of all patients). A medical treatment
without hospitalization was administered for 13 events;
hospitalization was required for 8 events. Major surgery
was performed in 2 patients: substitution of the femoral
head and amputation of the right lower limb, respectively.
One case of myocardial infarction was treated with coro-
nary stents. No patient died of toxicity. The characteristics
of patients with (N = 12) or without (N = 118) arterial
thrombotic events are shown in Table 5. The patients with
high or very high cardiovascular risk according to the
European Guidelines on cardiovascular disease prevention
in clinical practice,29 retrospectively assessed, had a signifi-
cantly higher probability of arterial thrombotic events
(Online Supplementary Figure S1). Among the other non-
hematologic and non-cardiovascular AEs, only fatigue (17%
Efficacy and safety of  frontline nilotinib in CML
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Table 3. Molecular response at milestones. 
BCR-ABL1IS ≤ 0.1% ≤ 0.01% ≤ 0.0032%
3 months 23% 2% 0
6 months 53% 12% 2%
12 months 57% 28% 7%
18 months 63% 31% 11%
24 months 65% 46% 17%
‘BCR-ABL1IS’: BCR-ABL/ABL% ratio, according to the International Scale. The response
rates were calculated by dividing the number of patients with that response at that time
by the total number of enrolled patients (N=130).
Figure 2. Outcome of all the 130 enrolled patients. The estimated 30-month
overall survival was 99% (95% CI, 91-100%), the 30-month estimated progres-
sion-free survival was 96% (95% CI, 89-98%), the estimated 30-month survival
without treatment discontinuation was 76% (95% CI, 67-83%).
Table 4. List of arterial thrombotic adverse events by year, all grades, irrespective of causality.
Type of event 1st 2nd 3rd Total Permanent Temporary
year* year* year* treatment treatment
discontinuation discontinuation
Lower limbsa 1 1 1 3 1 1
Coronaryb 2 2 2 6 4 1
Carotidc 1 0 0 1 0 1
Optic 0 1 0 1 0 0
Avascular necrosis of the femoral head 1 1 0 2 1 0
Total 5 5 3 13+ 6 3
*Duration of nilotinib treatment: ≤12 months, 130 patients; 13-24 months; 115 patients; > 24 months, 67 patients; a Amputation, 1 case; b Myocardial infarction, 1 case, stable or
unstable angina, 4 cases, troponin increase after atrial fibrillation, 1 case; c Transient ischemic attack, 1 case; + The 13 events were observed in 12 patients (one patient had two
events): the number of patients remaining on nilotinib was 6 (three patients assuming 600 mg daily, three patients assuming 300 mg daily). 
grade 1-2 and 1% grade 3), bone and muscle and joint pain
(22% grade 1-2 and 1% grade 3), and skin rash (29% grade
1-2 and 1% grade 3) were reported in more than 10% of
patients. Grade 3-4 laboratory abnormalities were as fol-
lows: grade 3 transaminase increase 2% (permanent treat-
ment discontinuation, 1 case), grade 3 bilirubin increase
5%, grade 3 and grade 4 lipase increase 12% and 2%,
respectively, and grade 3 amylase increase 1% (no pancre-
atitis). 
According to adapted ADA criteria, and considering the
maximum grade reached by each patient while on study,
47%, 11%, 5% and 6% of patients experienced a grade 1
(101-125 mg/dl), grade 2 (126-150 mg/dl), grade 3 (151-200
mg/dl) and grade 4 (>200 mg/dl) hyperglycemia, respective-
ly; 29% of patients had an increase of fasting glucose at 1
year, compared to baseline levels (P<0.001). According to
adapted ADA criteria, 47% of patients had a grade 1 (5.7-
6.4%), 10% a grade 2 (6.5-6.9%), 3% a grade 3 (7-7.9%)
and 5% a grade 4 (≥8%) glycated hemoglobin (HbA1c),
respectively, (maximum grade reached on our study); no
significant increase of glycated hemoglobin has been
observed from baseline. According to the AACE criteria, 40
patients (31%) experienced a borderline (200-239 mg/dL)
and 54 (42%) a high-risk (≥240 mg/dL) hypercholes-
terolemia (maximum grade reached on our study). A signif-
icant increase of cholesterol, both in LDL and HDL fractions
(P<0.001), and a significant reduction of triglycerides
(P<0.001) were detected at 1 year from baseline. The serum
glucose, HbA1c and lipid concentrations at each milestone
are shown in Figure 3 and Online Supplementary Table S3.
Discussion
The introduction and the extended clinical use of second
generation TKIs is becoming a very important issue in first-
line therapy for CML.2-4,10,30-38 They offer a treatment choice
that must be weighed for short- and long-term efficacy and
toxicity, and for cost-efficacy.16,39,40 The information on nilo-
tinib is limited to data coming from two company-spon-
sored studies, of which one was designed to compare nilo-
tinib and imatinib, and the other to confirm the rate of deep
molecular response on nilotinib.2-4,10 There are no data from
independent, investigator-sponsored, studies. This
GIMEMA trial was made possible thanks to the support of
Novartis Oncology Italy, who provided the drug free of
charge and a small unrestricted support. The study was
designed, conducted and analyzed by GIMEMA, so that
this is the first study providing company-independent data
on the treatment of newly diagnosed CP CML patients
with nilotinib 300 mg TD. The study has some strengths
and some limitations. The strengths are the independence
and the involvement of several clinical centers all over Italy.
The major limitation is the short time of observation, with
a minimum of 2 years, a median of 2.5 years, and a maxi-
mum of 3 years. The ENESTnd and the ENEST1st trials
were reported with a  minimum observation period of 6
and 2 years, respectively.4,10
Two major issues are important in the treatment of CML.
One issue is the rapidity31,41-44 and the depth45 of the molec-
ular response. We found that EMR was achieved less fre-
quently than in both ENEST trials, but that MMR (MR3.0),
MR4.0 and MR4.5 rates were in the same range of ENEST1st,
and even higher than in ENESTnd (Online Supplementary
Table S4).2-4,10 The significance of these differences cannot be
assessed because the three studies are different, with differ-
ent age distribution and proportion of high-risk (Sokal)
patients (28% in ENESTnd, 18% in ENEST1st, 21% in this
study), with different enrolment criteria and different
guidelines for dose reduction or treatment discontinuation.
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Table 5. Characteristics of patients with and without arterial thrombotic adverse events.
Variables Patients WITH events Patients WITHOUT events P
N = 12 N = 118
At baseline
Age, years, median (range) 62 (49-85) 47 (18-81) 0.002
Sex, male, N (%) 7 (58) 77 (65) 0.753
Body mass index, N (%)
< 25 6 (50) 69 (58) 0.162
25-29.9 3 (25) 35 (30)
30-34.9 2 (17) 10 (8)
≥ 35 1 (8) 4 (3)
ECOG ≥ 1, N (%) 4 (33) 17 (14) 0.104
Smokers, N (%) 4 (33) 22 (19) 0.257
Arterial hypertension, N (%) 4 (33) 24 (20) 0.287
Diabetes, N (%) 3 (25) 9 (8) 0.082
HbA1c, %, median (range) 6.2 (4.7-7.0) 5.9 (3.6-8.7) 0.809
Total cholesterol, mg/dL, median (range) 170 (126-315) 168 (81-260) 0.425
LDL, mg/dL, median (range) 111 (57-211) 103 (36-186) 0.692
HDL, mg/dL, median (range) 36 (15-75) 36 (11-79) 0.435
High or very high EURO CV score, N (%) 9 (75) 28 (24) < 0.001
On treatmenta
HbA1c, %, median (range) 6.4 (5.2-8.2)b 5.6 (3.8-8.7)c 0.023
Total cholesterol, mg/dL, median (range) 206 (140-272) 210 (107-328) 0.754
LDL, mg/dL, median (range) 128 (55-183) 133 (42-215) 0.598
HDL, mg/dL, median (range) 49 (29-90) 55 (10-103) 0.414
ECOG: performance status according to the Eastern Cooperative Oncology Group grading; HbA1c: glycated hemoglobin; EURO CV score: cardiovascular risk according to the
European Guidelines on cardiovascular disease prevention in clinical practice, version 2012 (31). LDL: low density lipoprotein; HDL: high density lipoprotein. aData at 6 months (the
results do not change considering other milestones, e.g. 3 months or 12 months); b66% of patients with HbA1c > 6.5% at 6 months were diabetic at baseline; c50% of patients with
HbA1c > 6.5% at 6 months were diabetic at baseline. 
It should be noted that the molecular response rates have
been calculated in two ways and reported as response rates
"at" and "by" different time points, where the rate "at" the
time point gives the actual proportion of patients who are
in that response at the given time point, and the rate "by"
the same time point gives the cumulative proportion of
patients achieving the response at least once before the
given time point. The estimated cumulative incidence of
response (response "by") helps to make a comparison
between two treatments, as in the ENESTnd study,2-4 but
overestimates the actual proportion (response "at") of the
patients who are in that response at that time, which is
important for clinical decisions. The response rates "at"
each time point are frequently lower than the values "by"
the same time points.
The second major issue is the so-called cardiovascular
toxicity, that includes different events, with different phys-
iopathologic mechanisms and different clinical relevance:
myocardial infarction, atrial fibrillation, superficial throm-
bophlebitis, arterial thrombosis, congestive heart failure,
stroke, and many others. The incidence, the severity and
the consequences of these complications are difficult to
assess and to compare, because they may depend on differ-
ent variables, including not only the patients characteristics,
the baseline cardiovascular risk, the prior treatments and
the drug dose,46-48 but also  the definition of the events, and,
importantly, the accuracy of the event reports, that depends
on the retrospective or prospective nature of the data collec-
tion. When the GIMEMA study was designed, the cardio-
vascular toxicity was not yet pointed out, apart from QTc
prolongation, and the cardiovascular risk at baseline was
not routinely assessed. However, the cardiovascular toxici-
ty was revealed as soon as patient enrolment began, so that
the identification and the reporting of CVAEs, in facts,
became prospective. However, monitoring,  prophylaxis,
and the treatment of CVAEs were left to local investigators,
because it was not possible to provide guidelines. Several
reports indicated a possible metabolic non-target effect of
Efficacy and safety of  frontline nilotinib in CML
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Figure 3. Metabolic effects of nilo-
tinib by time. (A) Distribution of
fasting glucose at milestones; (B)
Distribution of glycated hemoglo-
bin at milestones; (C) Distribution
of triglycerides at milestones; (D)
Distribution of total cholesterol at
milestones; (E) Distribution of low
density lipoprotein at milestones;
(F) Distribution of high density
lipoprotein at milestones. 
A
C
E
B
D
F
nilotinib, potentially related to CVAEs; importantly, in our
study, fasting glucose, glycated hemoglobin and serum
lipids were prospectively assessed.  Moreover, to evaluate
the clinical impact of metabolic effects, we decided to clas-
sify the abnormalities according to specific criteria, as rec-
ommended by ADA and AACE guidelines.27,28
With these caveats, it is possible to describe, but not to
compare, the 2-year incidence of major CVAEs in the pres-
ent trial and in the ENEST1st one:10 ischemic heart events
were 4.6% and 3.4% respectively; arterial thrombotic
events were 4.6% (including one case of retinal artery
occlusion  and two cases of avascular necrosis of the
femoral head) and 1.9%, respectively; arrhythmias were
2.3% and 0.7%, respectively; congestive heart failure was
reported in 0.8% and 0.3%, respectively. The incidence of
QTc prolongation (2.3% in the GIMEMA study) and of
venous thrombosis (3.1%) was not reported in the
ENEST1st study. With a median follow-up of 29 months, the
number of reported arterial thrombotic events was  higher
during the first and the second year, if compared to the third
year of treatment, but considering the number of patients
on nilotinib treatment, the yearly incidence was compara-
ble (Table 4). A linear increase of the cumulative incidence
of CVAEs over time was also described in the 
5-year update of the ENESTnd trial; the yearly incidence of
CVAE continues unabated after 5 years and may even
increase.3 In our study the cumulative probability of devel-
oping a CVAE was 7 % (95% CI, 4-13%) at 1 year and 13
% (95% CI, 8-20%) at 2 years (data not shown). We con-
firmed a significant increase of fasting glucose level during
nilotinib treatment, but we were not able to demonstrate
any significant increase of glycated hemoglobin. Similar
results were reported in the ENESTnd trial, in a sub-analysis
including only patients with normal glycemic status at base-
line:49 the majority of patients with hyperglycemia did not
meet the glycated hemoglobin criteria for diabetes. The
patients with arterial thrombotic events had a higher inci-
dence of cardiovascular risk factors at baseline (in particular,
a higher incidence of  diabetes was observed), and were eld-
erly (Table 5, Online Supplementary Figure S1). The exact
pathogenesis of fasting glucose alterations during nilotinib
is still controversial and probably related to insulin resist-
ance: both in the ENESTnd study49 and in the ENIGMA 2
study50 an increase in insulin production and a decrease of
fasting C-peptide were observed, with increased levels of
HOMA-IR and HOMA-β values. 
In conclusion, this independent study highlights the ther-
apeutic efficacy of nilotinib, confirming the rates, the veloc-
ity, and the depth of molecular response; moreover, it con-
firms that the risk of cardiovascular toxicity, including sev-
eral different events, is higher in patients with high cardio-
vascular risk, requiring specific measures of prophylaxis and
monitoring. 
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